Blue Crest Capital Management LTD Protagonist Therapeutics, Inc Transaction History

Blue Crest Capital Management LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$8.98 - $12.96 $191,992 - $277,084	-21,380 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$6.5 - $13.77 $46,098 - $97,656	7,092 Added 49.64%	21,380 $269,000
Q4 2018 Feb 14, 2019	SELL	$6.3 - $10.44 $32,841 - $54,423	-5,213 Reduced 26.73%	14,288 $96,000
Q3 2018 Nov 14, 2018	SELL	$6.82 - $11.26 $325,845 - $537,980	-47,778 Reduced 71.01%	19,501 $201,000
Q2 2018 Aug 14, 2018	BUY	$5.99 - $9.1 $403,001 - $612,238	67,279 New	67,279 $452,000

248

56.7M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.93B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

Stay updated on Blue Crest Capital Management LTD with notifications on news.